SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Munch-a-Biotech Today
An SI Board Since December 1998
Posts SubjectMarks Bans
3158 136 0
Emcee:  Biomaven Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1408Report: Glaxo Tipped to Buy Bayer Unit Reuters Saturday, November 16, 2002; 10sim1-11/17/2002
1407Celgene To Acquire Anthrogenesis For $45 Million Wednesday November sim1-11/13/2002
1406NEW BRUNSWICK, N.J. and WARMINSTER, Pa., Nov. 13 /PRNewswire-FirstCall/ -- Johnsnigel bates-11/13/2002
1405Lance, I am not sure why Enzon bought Abelcet in first place. It is not true lipMiljenko Zuanic-11/12/2002
1404It wouldn't have anything to do with Enzon's acquisition of abelcet fromLance Bredvold-11/12/2002
1403The only reason (that I see) they want to buy ENZON is Peg-Taxol. Low MW Peg-fraMiljenko Zuanic-11/12/2002
1402A logical munch should it happen - because of the savings in royalty, SGP can afBiomaven-11/12/2002
1401INCY spends some more cash -   PALO ALTO, Calif. & SAN DIEGO--(BUnigel bates-11/12/2002
1400OGS narrows M&A focus to Europe and UK Tuesday November 12, 4:47 am ET By BeIcebrg-11/12/2002
1399Baxter to Acquire Epic Therapeutics, Inc. DEERFIELD, Ill. and NORWOOD, Mass., Nnigel bates-11/11/2002
1398Hyseq munches VGNX - Message 18219216 - to become the company with no name.nigel bates-11/11/2002
1397Not necessarily - after all GSK didn't buy EXEL. If sector consolidation hanigel bates-10/29/2002
1396Merger Talk: Are cash-rich biotechs now sitting ducks? Monday Octobesim1-10/28/2002
1395Bottom line would seem to be relative valuation. Another 12 months though, and snigel bates-10/23/2002
1394British Biotech eyes new deal By Mark Potter LONDON (Reuters) - British BiotecIcebrg-10/23/2002
1393FRANKFURT -(Dow Jones)- MorphoSys AG , the Munich-based biotechnology company, tnigel bates-10/23/2002
1392Associated Press King Pharmaceuticals Buys Meridian Monday October 21, 10:35 am keokalani'nui-10/21/2002
1391Bidders form orderly PowderJect queue By Mark Potter LONDON (Reuters) - SharesIcebrg-10/21/2002
1390Reuters Chiron offers to buy PowderJect - source Sunday October 20, 11:37 am ET dalroi-10/20/2002
1389I dont think ebio is for sale yet lots of insider buying at these levels i'dalroi-10/16/2002
1388EBIO ? In any event, given the price, IVGN is getting the customer list just abnigel bates-10/16/2002
1387A slightly odd fit, IMO; EBIO would have made more sense. Even though IVGN getstuck-10/15/2002
13861 Press Release Source: DiaSys Corp. DiaSys and Merck Centroamericana S.A. iYAR7888-10/15/2002
1385Procyon BioPharma (TSX-PBP) The last three months have been very much maintainithebeach-10/15/2002
1384SAN DIEGO & BETHESDA, Md.--(BUSINESS WIRE)--Oct. 15, 2002--Invitrogen Corp. nigel bates-10/15/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News